Why the study?
Mitral regurgitation causes substantial morbidity and mortality, and M-TEER has evolved over 15 years into a guideline-recommended treatment for severe primary or secondary mitral regurgitation.
This review highlights the evolution of M-TEER as a safe, effective, and guideline-recommended therapy for severe mitral regurgitation that significantly improves patient quality of life.
Supports M-TEER adoption in severe MR; leaves open need for prospective trials on durability and subgroups.
INTRODUCTION: Mitral regurgitation (MR) is associated with substantial morbidity and mortality. Within the past 15 years, mitral valve edge-to-edge repair (M-TEER) has developed from an experimental approach to a guideline-recommended, safe, and effective treatment option for patients with severe primary or secondary mitral regurgitation. AREAS COVERED: This review covered relevant publications of M-TEER and summarizes the development of M-TEER devices within the last 15 years. It outlines anatomical challenges which drove the evolution of M-TEER devices, provides an overview about the current state of clinical application and research, and offers an outlook into the future of transcatheter mitral valve treatment. EXPERT OPINION: The development and refinement of new M-TEER device generations offer the possibility to treat a wide range of mitral valve anatomies. Choosing the best device for the individual anatomic properties of the patients and considering comorbidities is the key to maximized MR reduction, minimalized complication rates, and thus optimized postinterventional prognosis. Independent from prognostic implications, quality of life has become an important patient-centered outcome that can be improved by M-TEER in virtually all patients treated.
No takes yet. Share an insight, caveat, or question.
Stolz et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: